Evidence map›Paper›PMID 40125625›Full record

ArticleDrug development research2025

Design, Synthesis and Anti-Influenza Virus Activity of 4-Tert-Butyl-N-(3-Oxo-1-Thia-4-Azaspiro[4.5]Dec-4-yl)Benzamide Derivatives That Target Hemagglutinin-Mediated Fusion.

Gözde Çınar, Zeynep Alikadıoğlu, Özge Soylu-Eter, Lieve Naesens, Gökçe Cihan-Üstündağ

Abstract read
In one paragraph

Article in Drug development research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gözde ÇınarInstitute of Health Sciences, Istanbul University, Istanbul, Turkey.ORCID 0000-0002-0309-663X
Zeynep AlikadıoğluDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.
Özge Soylu-EterDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Fırat University, Elazığ, Turkey.
Lieve NaesensDepartment of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Gökçe Cihan-ÜstündağDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.

Funding

We would like to thank Professor Gültaze Çapan for sharing expertize in medicinal chemistry. L.N. wishes to thank the team of L. Persoons for dedicated technical assistance. This workstudy was supported by Scientific Research Projects Coordination Unit of Istanbul University (Grant Number: 32246).
6 · The paper itself

Abstract

Hemagglutinin (HA) is a viral glycoprotein that mediates influenza virus entry into the host cell and is considered a relevant viral target. We here report the identification of a class of 4-tert-butylphenyl-substituted spirothiazolidinones as HA-mediated fusion inhibitors with specific activity against influenza A/H3N2 virus. The novel spirocyclic compounds were achieved by using one-pot cyclocondensation method and the chemical structures were characterized by IR,

Indexed as

Antiviral AgentsBenzamidesHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H3N2 SubtypeSpiro CompoundsAnimalsDogsDrug DesignHumansMadin Darby Canine Kidney CellsMolecular Docking SimulationStructure-Activity RelationshipVirus InternalizationAntiviral AgentsBenzamidesHemagglutinin Glycoproteins, Influenza VirusSpiro Compoundsantiviralhemagglutinininfluenza virusspirothiazolidinonesynthesis

Identifiers

PMID40125625
PMCPMC11931604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.